International Liver Congress (ILC) 2021

High cholesterol during pregnancy serious heart attack in offspring

Tenofovir alafenamide may prevent HBV mother-to-child transmission

Roshini Claire Anthony, 20210819180001

Tenofovir alafenamide (TAF), administered during the second or third trimester of pregnancy, may prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection, according to two studies presented as posters at ILC 2021.

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

Roshini Claire Anthony, 20210806180001

The addition of amoxicillin/clavulanate to prednisolone does not extend survival among patients with severe alcoholic hepatitis, though it may reduce infection risk, according to a French study presented at ILC 2021.

Tenofovir tied to lower risk of severe COVID-19 in HBV patients

Pearl Toh, 20210718143500

Patients with chronic hepatitis B virus (HBV) infection who were treated with tenofovir had a lower risk of developing severe COVID-19 illness than those treated with entecavir, according to a study presented at the EASL International Liver Congress (ILC) 2021.

Phase II trial updates underpin benefit of efruxifermin for NASH

Audrey Abella, 20210716100000

In individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) with fibrosis, the reductions in liver fat content (LFC) with efruxifermin correlated with improvements in markers of liver injury, fibrosis, metabolic parameters, and histologic features, according to updates from the phase IIa BALANCED study presented at ILC 2021.

New liver dialysis device – how safe in cirrhosis?

Elvira Manzano, 20210715000000

A novel liver dialysis device appeared safe vs standard of care (SoC) in patients with acute on chronic liver failure (ACLF) in a small randomized study in Europe.

Phase III data support resmetirom potential for NAFLD/NASH

Audrey Abella, 20210714154128

In individuals with nonalcoholic fatty liver disease (NAFLD) or presumed nonalcoholic steatohepatitis (NASH), resmetirom, an investigational, once-daily, oral selective thyroid hormone receptor beta agonist, significantly improved several hepatic and cardiovascular (CV) parameters, according to the findings of the phase III MAESTRO-NAFLD1 trial presented at ILC 2021.